|
2021, May 6 - 13:12
|
|
RECORDATI: FIRST QUARTER 2021 RESULTS AND 2021-2023 THREE-YEAR PLAN APPROVED; 2023 REVENUE FORECAST BETWEEN € 1,900 AND € 2,000 MILLION
|
|
|
2021, April 28 - 09:37
|
|
RECORDATI TO PRESENT THE FIRST QUARTER 2021 RESULTS AND THE 2021-2023 STRATEGY AND OUTLOOK UPDATE
|
|
|
2021, April 22 - 12:22
|
|
RECORDATI: REGISTRATION WITH THE COMPANIES’ REGISTER OF THE MERGER DEED BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. COMPLETED
|
|
|
2021, April 20 - 12:47
|
|
RECORDATI: SHAREHOLDERS APPROVE THE 2020 ACCOUNTS. DIVIDEND € 1.05 PER SHARE (+5.0% vs 2019).
|
|
|
2021, April 12 - 18:13
|
|
RECORDATI: THE MERGER DEED RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. HAS BEEN EXECUTED
|
|
|
2021, March 24
|
|
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN JAPAN
|
|
|
2021, March 23
|
|
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE
|
|
|
2021, March 18 - 16:42
|
|
RECORDATI: BOARD APPROVES THE 2020 ACCOUNTS. SALES € 1,448.9 MILLION (-2.2%), EBITDA € 569.3 MILLION (+4.7%), ADJUSTED NET INCOME € 410.4 MILLION (+7.3%). 2020 DIVIDEND € 1.05 (+ 5.0 %)
|
|
|
2021, February 22 - 18:25
|
|
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS
|
|
|
2021, February 22 - 12:58
|
|
RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING AND NET INCOME. EBITDA +4.7% AND ADJ NET INCOME +7.3%
|
|
|
2021, January 29 - 18:06
|
|
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
|
|
|
2021, January 26
|
|
RECORDATI: CARBAGLU receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia
|
|
